Speedy Clearance Of COVID-19 Vaccines Concerns Experts In India
In Pandemic Emergency, Difficult Questions Of Science, Hope And Doubt Abound
No one wants to take away from India’s flair and prowess in the vaccines segment, but there should be no place for doubt when it comes to rigor in scientific and regulatory processes. Experts have raised questions around the restricted emergency use clearance of two COVID-19 vaccines in India.
You may also be interested in...
India gave a conditional accelerated approval to AstraZeneca partner Serum Institute and separately, to Bharat Biotech for their COVID-19 vaccines. With the latter’s vaccine still in Phase III trials, the unprecedented decision caused a flutter as the regulator had earlier said an EUA would not be granted unless trials are completed.
State-owned China National Biotec Group becomes the first to get the greenlight for its inactivated virus-based vaccine to prevent COVID-19.
UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.